Cytokinetics, Incorporated Shares of Common Stock (par value $0.001 per share) Amended and Restated Controlled Equity OfferingSM Sales AgreementSales Agreement • March 1st, 2023 • Cytokinetics Inc • Pharmaceutical preparations
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), confirms its amended and restated agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
FOURTH AMENDMENT TO LEASELease • March 1st, 2023 • Cytokinetics Inc • Pharmaceutical preparations
This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of October 12, 2022, by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant").
SECOND AMENDMENTSecond Amendment • March 1st, 2023 • Cytokinetics Inc • Pharmaceutical preparations • New York
This SECOND AMENDMENT (this “Amendment”), effective as of December 8, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 350 Oyster Point Boulevard, South San Francisco, CA 94080 (“Borrower”).
CONSENT AND AMENDMENTConsent And • March 1st, 2023 • Cytokinetics Inc • Pharmaceutical preparations • New York
This CONSENT AND AMENDMENT (this “Amendment”), effective as of June 30, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 350 Oyster Point Boulevard, South San Francisco, CA 94080 (“Borrower”).
